Concordia Names Six Drugs Targeted By UK Competition Inquiry

 
• By Ian Schofield

Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.

Hurdles
The CMA is continuing its pursuit of unfair competition

More from Legal & IP

More from Pink Sheet